Media Center | Acadia Pharmaceuticals Inc.

Media Center

2020 | 2019 | 2018 | Archive

COMPANY FACTS
Acadia is trailblazing breakthroughs in neuroscience to elevate life. For more than 25 years we have been working at the forefront of healthcare to bring vital solutions to people who need them most. We developed and commercialized the first and only approved therapy for hallucinations and delusions associated with Parkinson’s disease psychosis. Our late-stage development efforts are focused on dementia-related psychosis, negative symptoms of schizophrenia and Rett syndrome, and in early-stage clinical research we are exploring novel approaches to pain management, and cognition and neuropsychiatric symptoms in central nervous system disorders.
Headquartered in San Diego, California
R&D Center, Princeton, New Jersey
Stock is listed on NASDAQ: ACAD
Chief Executive Officer:
Stephen R. Davis

Media Contact